VT Valuation
Is A018290 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of A018290 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: A018290 (₩30000) is trading below our estimate of fair value (₩39421.27)
Significantly Below Fair Value: A018290 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for A018290?
Key metric: As A018290 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is A018290's PE Ratio? | |
|---|---|
| PE Ratio | 20.2x |
| Earnings | ₩52.64b |
| Market Cap | ₩1.06t |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.6x |
| Enterprise Value/EBITDA | 11.2x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does A018290's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 16.5x | ||
A278470 APR | 21.5x | 25.7% | ₩2.0t |
A192820 Cosmax | 20.1x | 27.3% | ₩1.5t |
A241710 Cosmecca Korea | 16.7x | 22.4% | ₩575.7b |
A002790 AMOREPACIFIC Group | 7.7x | 3.2% | ₩1.8t |
A018290 VT | 20.2x | n/a | ₩1.1t |
Price-To-Earnings vs Peers: A018290 is expensive based on its Price-To-Earnings Ratio (20.2x) compared to the peer average (16.5x).
Price to Earnings Ratio vs Industry
How does A018290's PE Ratio compare vs other companies in the KR Personal Products Industry?
| 1 Company | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
A900120 CXI Healthcare Technology Group | 0.8x | n/a | US$15.93m |
| 1 Company | Estimated Growth | Market Cap |
|---|
Price-To-Earnings vs Industry: A018290 is expensive based on its Price-To-Earnings Ratio (20.2x) compared to the KR Personal Products industry average (17.3x).
Price to Earnings Ratio vs Fair Ratio
What is A018290's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 20.2x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate A018290's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
NeoPharm
₩193.5b
Engages in the manufacturing and sale of skin care products in South Korea.
A092730
₩11,840.00
7D
-9.1%
1Y
3.0%
NOVAREXLtd
₩135.4b
Manufactures, wholesales, and retails health and functional foods in South Korea and internationally.
A194700
₩7,650.00
7D
-18.7%
1Y
-31.5%
Cosmecca Korea
₩600.2b
Engages in the research and development, manufacture, and sale of skincare products in South Korea and internationally.
A241710
₩53,900.00
7D
-13.6%
1Y
44.3%